Palbociclib Treatment Supported for Black and Hispanic Patients With HR+, HER2- Beast Cancer
December 9th 2021Data from a pooled analysis confirm that patients who self-identify as Black or Hispanic can safely benefit from treatment with palbociclib plus endocrine therapy for hormone receptor–positive, HER2-negative advanced breast cancer.
Read More
CNS-PFS Prolonged With Tucatinib Plus Palbociclib/Letrozole in HR+/HER2+ Breast Cancer
December 8th 2021A non-chemotherapy–based targeted regimen comprised of tucatinib, palbociclib, and letrozole was found to prolong central nervous system (CNS) progression-free survival (PFS) in patients with hormone receptor–positive, HER2-positive breast cancer.
Read More
Premenopausal ER+ Breast Cancer Recurrence Reduced Significantly With Aromatase Inhibitors
December 8th 2021Compared with tamoxifen, aromatase inhibitors were revealed to be more effective in reducing the rate of recurrence in ER+ breast cancer among premenopausal women receiving ovarian suppression.
Read More
Poor Accuracy Seen with Standard IHC in Identifying Low HER2 Expression in Breast Cancer
December 8th 2021Data presented at the San Antonio Breast Cancer Sympsium found that in patients with a low HER2 immunohistochemistry (IHC) score of 0 or 1+, poor agreement in the evaluation of these patients exist using standard HER2 assays.
Read More
Outcomes in Early Hormone Receptor-Positive or- Negative Breast Cancer Not Improved with Metformin
December 7th 2021Improved invasive disease-free survival or overall survival rates for patients, regardless of hormone receptor status, was not improved with metformin, according to results of a phase 3 trial.
Read More
Multigene Sequencing Used to Choose Matched Targeted Therapy in mBC Show PFS Improvement
December 7th 2021A pooled analysis of results from the randomized phase 2 SAFIR02_BREAST and SAFIR-PI3K trials show promise for the use of multigene sequencing to select targeted therapy for metastatic breast cancer.
Read More
PFS Doubles With Fulvestrant/Palbociclib Following AI/Palbociclib in HR-Positive, HER2-Negative mBC
December 7th 2021Findings from the phase 3 PADA-1 trial reveal promising progression-free survival results when treatment with fulvestrant/palbociclib follows treatment with an aromatase inhibitor plus palbociclib in a metastatic breast cancer subgroup.
Read More
Efficacy and Safety Assessment of Frontline Lenvatinib Plus Pembrolizumab Underway for nccRCC
November 6th 2021The frontline combination of lenvatinib and pembrolizumab is under investigation as a treatment option for patients with non-clear cell renal cell carcinoma in the recently launched phase 2 KEYNOTE-B61 trial.
Read More